Remoxipride

drugbox
IUPAC_name = 3-Bromo-N- [ [("2S")-1-ethylpyrrolidin-2-yl] methyl] -2,6-dimethoxy-benzamide


CAS_number = 117591-79-4
ATC_prefix = N05
ATC_suffix = AL04
PubChem = 54477
DrugBank = DB00409
chemical_formula =
molecular_weight = 371.27 g/mol
bioavailability = C₁₆H₂₃BrN₂O₃
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.

Clinical trials

Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.

External links

* [http://www.acnp.org/G4/GN401000123/CH121.html Herbert Y. Meltzer, Atypical Antipsychotic Drugs, 2000]